- Meeting abstract
- Open access
- Published:
The pharmacotherapy of depression with EPA
Annals of General Psychiatry volume 9, Article number: S23 (2010)
This lecture considers the pharmacotherapy of depression with EPA under the following headings:
-
Epidemiological evidence
-
Biochemical evidence
-
First trial of pure EPA in severe treatment-resistant depression
-
Subsequent randomized double-blind placebo-controlled trials
-
Putative mechanisms.
Results obtained from our own group, including structural neuroimaging and 31-phosphorus neurospectroscopy findings, showing an association of EPA treatment of depression with a marked decrease in cerebral phosphodiesters, a marked increase in cerebral phosphomonoesters and reduced lateral ventricular volume, will also be presented.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Puri, B.K. The pharmacotherapy of depression with EPA. Ann Gen Psychiatry 9 (Suppl 1), S23 (2010). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/1744-859X-9-S1-S23
Published:
DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/1744-859X-9-S1-S23